AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

Profiling of Energy Metabolism in Olanzapine-Induced Weight Gain in Rats and Its Prevention by the CB1-Antagonist AVE1625

(2010) Michaela Liebig et al.   Obesity

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

(2010) Patrik Roser et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment

(2009) Ina Weiner et al.   BEHAVIOURAL BRAIN RESEARCH

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

(2009) Fabrício A. Moreira et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia

(2009) Segev Barak et al.   NEUROPSYCHOPHARMACOLOGY

Activation of Cannabinoid-1 Receptors Disrupts Sensory Gating and Neuronal Oscillation: Relevance to Schizophrenia

(2008) Mihály Hajós et al.   BIOLOGICAL PSYCHIATRY

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus

(2008) Gunnar Thiemann et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat

(2008) Mark D. Black et al.   PSYCHOPHARMACOLOGY